• About us
  • Science and Pipeline
  • Investors
  • Contact us
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Aug 6, 2026 | Press Releases

Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcementsKing of Prussia, Pennsylvania–(Newsfile Corp. – August...

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Jul 22, 2026 | Press Releases

Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – July 22, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Jul 22, 2026 | Press Releases

Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – July 22, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics...

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Jul 21, 2026 | Press Releases

Brings extensive experience in patient care, dermatologic research and commercializationKing of Prussia, Pennsylvania–(Newsfile Corp. – July 21, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

Jul 15, 2026 | Press Releases

Securing additional patent protection in the United States, Canada, and Japan for INTASYL CompoundsKing of Prussia, Pennsylvania–(Newsfile Corp. – July 15, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Jun 26, 2026 | Press Releases

Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – June 26, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics...
« Older Entries
Next Entries »

Recent Posts

  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
  • Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
  • Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
  • Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Recent Comments

No comments to show.
Email Alerts

Stay up to date on news and investor alerts

Sign up now

© 2026 Phio Pharmaceuticals

  • Follow
  • Follow
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us